Peptides for Disease Research

We’re rapidly producing custom peptides and peptide libraries for the major proteins of SARS-COV-2. With high quality products available fast for researchers combating Covid19, come and see Mimotopes for all of your peptide needs.

Custom Peptide Libraries

The advantage of our proprietary parallel synthesis technology is that Mimotopes can synthesise hundreds of peptides simultaneously, and thus greatly reduce the price and time to delivery.

High quality Peptide Libraries affordable prices

30 Years Experience

Mimotopes is the founder of peptide library technology. We have only continued to grow and learn over the decades – now our expertise is unrivaled.

We work tirelessly to stay ahead of the game to ensure, as always, that we supply the best possible products, including SARS-CoV-2 peptides.

Efficient & Economical Screening Solutions

PepsetTM PeptideLibraries have dozens of potential applications. With applications in covid19 vaccine and drug development, disease screening, and epitope mapping, a peptide library can be exclusively designed to your specifications, for your research. 

  • Discover crucial residues with an Alanine Scan Library
  • Map epitopes with an Overlapping Library
  • Narrow down the shortest active sequences with a Truncated Library

Dozens of Options to Customise

A standard PepSetTM Peptide Library can be supplied as with a precise length and offset designed to best suit your assays, but that’s not all. Modifications and labels can be applied to the termini or even within the sequence. Arrange a consultation to discuss your options and design your library.

Contact us today for a peptide quote! 

Australia

☎ +61 3 9565 1111

✉ australia@mimotopes.com

North and South America 

☎ +1 651 603 0909

 useast@mimotopes.com
     uswest@mimotopes.com

asia

☎ +61 3 9565 1111

✉ asia@mimotopes.com


UK / Europe / Africa / Middle East

☎ +44 (0)151 556 0547

✉ europe@mimotopes.com

Contact us today for a peptide quote! 

Australia

☎ +61 3 9565 1111

australia@mimotopes.com

North and South America 

☎ +1 651 603 0909

  ✉ useast@mimotopes.com 
  ✉ uswest@mimotopes.com

asia

☎ +61 3 9565 1111

✉ asia@mimotopes.com

UK/ Europe/ Africa/ Middle East

☎ +44 (0)151 556 0547

✉ europe@mimotopes.com

Go to article: Home | Under the microscopeGo to article: In this issueGo to article: SHL Medical Company InsightGo to article: SHL MedicalGo to article: ContentsGo to article: MimotopesGo to article: NewsGo to article: VEGA AustraliaGo to article: Covid-19 executive briefing by GlobalDataGo to article: WipotecGo to article: Nasal spray vaccine for Covid-19Go to article: Datwyler Company Insight Go to article: DatwylerGo to article: Covid-19 clinical trials continue to rise in BrazilGo to article: BiogazelleGo to article: AstraZeneca’s Phase I / II Covid-19 vaccine trial Go to article: SwiftpakGo to article: MTPA resumes screening and enrolment for global Phase III clinical trial of MT-1Go to article: Biesterfeld Go to article: The pharma industry briefingGo to article: From antitoxins to Covid-19 drugs: charting the history of antibody drugsGo to article: Quality control: pharma manufacturing inspections explainedGo to article: Molnár-Institute Company InsightGo to article: Molnar-InstituteGo to article: Oxytocin: the therapeutic potential of the ‘love hormone’Go to article: AI-enabled risk detection in pharma manufacturingGo to article: Dr. Paul LohmannGo to article: Addressing the long-term effects of Covid-19Go to article: Eyes on the prize: the latest in retinitis pigmentosa gene therapiesGo to article: HOF Sonderanlagenbau Company Insight Go to article: HOF SonderanlagenbauGo to article: Breaking the taboo: disrupting the fertility sectorGo to article: Neutralising the gluten threat: are we on the cusp of a coeliac disease breakthrough? Go to article: Nolato Company Insight Go to article: NolatoGo to article: Pharmacovigilance case intake: why the hesitation to automate?Go to article: Deals in brief powered by GlobalDataGo to article: The key list powered by GlobalDataGo to article: Zenatek Go to article: Global markets and indices powered by GlobalDataGo to article: Macro-economic indicators (1 of 2) powered by GlobalDataGo to article: Macro-economic indicators (2 of 2) powered by GlobalDataGo to article: EventsGo to article: Next issue